# Evernorth EncircleRx

**Type:** Managed-access program (PBM infrastructure)
**Parent:** Evernorth (Cigna)
**Domain:** GLP-1 utilization management
**Status:** Active

## Overview

Evernorth EncircleRx is a managed-access operating system for GLP-1 receptor agonists, managing utilization and cost across 9 million enrolled lives as of 2026.

## Program Structure

**Cost containment mechanisms:**
- 15% cost cap guarantee
- 3:1 savings guarantee (alternative structure)
- $200 copay cap on Wegovy and Zepbound (added 2025)

**Operational scale:**
- 9 million enrolled lives
- ~$200 million saved since 2024

## Strategic Context

EncircleRx represents Evernorth's response to GLP-1 fiscal pressure (10x PMPM increase 2023-2024) by building multi-layer infrastructure beyond traditional formulary management. The program competes with:
- Optum Rx Weight Engage (UHC)
- Manufacturer direct-to-employer channels (Lilly Employer Connect, Novo Nordisk DTE)

## Timeline

- **2024** — EncircleRx launched
- **2025** — Added $200 copay cap on Wegovy and Zepbound
- **2026** — Managing 9M lives, ~$200M cumulative savings reported